Neurophyxia is a leading pharmaceutical company based in 's-Hertogenbosch, the Netherlands. Established in 2008, the company specializes in the development of innovative neuroprotectant treatments. Backed by a dedicated academic team and strong business and investment partners, Neurophyxia has successfully advanced their neuroprotectant, 2-iminobiotin (2-IB), from early preclinical stages to Phase II Clinical Trials.

This groundbreaking drug aims to treat cerebral reperfusion injury caused by stroke, cardiac arrest, and birth asphyxia. The company's management team consists of experienced professionals in the field of neurology and pharmaceutical development. Co-founder and Chief Scientific Officer, Cacha Peeters-Scholte, MD, PhD, is a renowned pediatric neurologist with a focus on fetal and neonatal neurology.

Chief Pharmaceutical Development Officer, Leo G. J. Drs.

Elize van der Hoeven, PharmD, the Chief Operation Officer, oversees the daily operations and coordinates the team of specialist consultants. The safety officer, Huibert Tjabbes, has extensive experience in medical innovation management. With a strong commitment to neuroprotection and the development of cutting-edge therapies, Neurophyxia is at the forefront of advancements in the field of neuroscience.

For more information, please visit their website or contact them via email